Moderna outlines mRNA pipeline progress at Science Day event
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
Moderna Science Day Highlights Expanding Potential of mRNA Platform
June 25, 2026 7:01 AM EDTProvides broad overview of Company's research and early development programs expected to continue to fuel future growth
Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell engager mRNA-2151 in ovarian cancer
Introduces in vivo CAR-T modality with mRNA-6007 moving into early development for autoimmune diseases
CAMBRIDGE, MA / ACCESS Newswire / June 25, 2026 / Moderna, Inc. (NASDAQ: MRNA) today announced research and early development updates at its Science Day... More
